enterococcus faecalis

Sclareolide (Norambreinolide) is a sesquiterpene lactone natural product derived from various plant sources including Salvia yosgadensis, Salvia sclarea, and cigar tobacco. It is a close analog of Sclareol, a plant antifungal compound.

Cefuroxime (Cephuroxime) is an orally active second-generation cephalosporin antibiotic with antimicrobial activity that inhibits both Gram-positive and Gram-negative bacteria, and is used in the study of soft tissue infections.

Dermaseptin acetate, a peptide isolated from frog skin, exhibits potent antimicrobial activity against bacteria, fungi, and protozoa at micromolar concentration[1].

10-Isobutyryloxy-8,9-epoxythymol isobutyrate was found to be a major constituent of Inula helenium and Inula royleana root cultures. 10-Isobutyryloxy-8,9-epoxythymol isobutyrate showed moderate antimicrobial activity against Staphylococcus aureus, Enterococcus faecalis, Escherischia coli, Pseudomonas aeruginosa and Candida albicans. 10-Isobutyryloxy-8,9-epoxythymol isobutyrate is therefore used in antimicrobial natural product research systems to investigate plant-derived antimicrobial compound activity spectra and microbial susceptibility profiling in bacterial and fungal models.

ROS inducer 8 (Compound 11g) acts as an inhibitor of glutathione (GSH) and promotes the accumulation of reactive oxygen species (ROS) in Enterococcus faecalis, exhibiting antibacterial properties. It is capable of disrupting biofilms and inhibiting S. aureus and E. faecalis with minimum inhibitory concentrations (MICs) of 8 μg/mL and 2 μg/mL, respectively, demonstrating a post-antibiotic effect. Additionally, ROS inducer 8 shows low hemolytic toxicity on sheep red blood cells with an HC50 greater than 1280 μg/mL.

Antibacterialagent 272 (Compound Z22) is a potential antibacterial agent that targets the DNA and DNA-topoisomerase II (DNA-Topo II) complex. It exhibits strong antibacterial activity, with a minimum inhibitory concentration (MIC) of 1 μg/mL against Staphylococcus aureus 25923 and 29213, 2 μg/mL against Staphylococcus epidermidis 12228, 2-4 μg/mL against Enterococcus faecalis, and 4 μg/mL against Pseudomonas aeruginosa 9027 and 27853. Antibacterialagent 272 binds by intercalating between DNA base pairs, disrupting the normal function of bacterial DNA, and is suitable for research into bacterial infectious diseases.

QPyN16Th is an N-palmitoylated cationic thiazolidine antibiotic. It exhibits selective activity against Gram-positive bacteria such as Enterococcus faecalis, Staphylococcus aureus, and methicillin-resistant Staphylococcus aureus (MRSA), with a MIC of 1.95 μM for Gram-negative bacteria. QPyN16Th can induce membrane permeabilization and depolarization in MRSA, along with ROS generation. It improves survival rates in a zebrafish model with intramuscular MRSA infection.

Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidase (SPase I) with an IC50 of 4.475 μM and a Kd of 16.3 μM. It disrupts bacterial membranes and has biofilm-clearing capabilities. This agent exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, and Streptococcus suis, respectively. Despite its effectiveness against multidrug-resistant strains, it shows weaker activity against Gram-negative bacteria, such as Escherichia coli and Salmonella spp. (MIC > 64 μg/mL). Anti-infective agent 12 has low hemolytic properties and demonstrates significant efficacy in mouse skin infection models. It reduces the risk of resistance emerging from single-target mutations and can be used in the study of multidrug-resistant Gram-positive bacterial infections.

E3709 is an antibacterial agent demonstrating significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridium, and Corynebacterium. E3709 can be utilized in research related to infections caused by Gram-positive bacteria.

Azithromycin-amide-C3-amide-quinoxaline (Compound 5f) is a derivative of Azithromycin and serves as an antibacterial agent. It inhibits topoisoisomerase I with an IC50 of 120.7 μM. The compound binds to the Escherichia coli 70S ribosome with a Kd of 0.8 nM and suppresses bacterial translation with an IC50 of 0.7 μM. It shows antibacterial activity against Streptococcus pneumoniae ATCC 49619, Staphylococcus aureus ATCC 29213, and Enterococcus faecalis ATCC 29212, with MIC values of 0.06 μg/mL, 2 μg/mL, and 0.5 μg/mL, respectively. Additionally, this compound exhibits anticancer activity against prostate and colorectal cancer.

Teicoplanin aglycone is an antibacterial glycopeptide antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including Enterococcus faecalis and methicillin-resistant Staphylococcus aureus.

T145 inhibits growth of Enterococcus faecalis, Staphylococcus aureus and Mycobacterium tuberculosis (Mtb) with sub μg/ml potencies that are potentially therapeutically valuable. T145 minimizes selection of spontaneous resistant mutants, a trait that prolo

ABT-719 is a 2-pyridinone antimicrobial agent that is more effective against Enterococcus faecalis strains than ciprofloxacin and vancomycin, which showed resistance to ciprofloxacin and vancomycin covering a range of MIC.

4aα,7α,7aα-Nepetalactone is a natural terpenoid lactone exhibiting antibacterial activity against E. coli, P. aeruginosa, S. aureus, and others.

Wychimicin C, a spirotetronate polyketide isolated from the rare actinomycete, Actinocrispum wychmicini strain MI503-AF4, demonstrates potent antibacterial efficacy. Specifically, it exhibits significant activity against methicillin-resistant Staphylococcus aureus (IC 50 =0.125-0.5 μg/mL) and Enterococcus faecalis/faecium (IC 50 =0.125-0.25 μg/mL) [1] [2].

Wychimicin A, a spirotetronate polyketide isolated from the rare actinomycete Actinocrispum wychmicini strain MI503-AF4, exhibits potent antibacterial activity. Specifically, it demonstrates efficacy against methicillin-resistant Staphylococcus aureus (IC 50 = 0.125-0.5 μg/mL) and Enterococcus faecalis/faecium (IC 50 = 0.125-0.25 μg/mL) [1] [2].

Enterocin K1 (EntK1) is a ribosomally synthesized bacteriocin with potent antibacterial activity against Vancomycin-resistant Enterococcus (VRE), specifically targeting Enterococcus faecalis through interaction with the Eep protein on the bacterial membrane. The compound shows promise for research into VRE infections [1].

COB1 pheromone, a bacterial sex pheromone, effectively inhibits the multidrug-resistant Enterococcus faecalis V583 [1].

GP-2B, an antimicrobial peptide, exhibits antibacterial activity against Gram-positive strains, with a minimum inhibitory concentration (MIC) ranging from 8 to 128 μg/mL for S. aureus and Enterococcus faecalis [1].

Parvodicin B1 is a glycopeptide antibiotic effective against Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Enterococcus faecalis. It functions by inhibiting the synthesis of bacterial cell walls.

Fluoropolyoxin L exhibits inhibitory activity against Escherichia coli and Enterococcus faecalis.

Parvodicin A is a glycopeptide antibiotic that exhibits inhibitory effects against Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, and Enterococcus faecalis.

Parvodicin C4 is a glycopeptide antibiotic that exhibits inhibitory effects against Staphylococcus aureus, Staphylococcus epidermidis, hemolytic Staphylococcus, and Enterococcus faecalis.

Piptamine exhibits a broad antibacterial spectrum, with inhibitory MIC (μg/mL) values against various microorganisms as follows: Staphylococcus aureus (0.78-6.25), Enterococcus faecalis (1.56), Bacillus subtilis (1.00), Escherichia coli (12.5), and Candida albicans (6.25).